Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

US Is a hotspot for Biopharmaceuticals leaders

BioSpace 22 [BioSpace Editorial Staff 9/21/2020 ; The Home of the Life Sciences Industry. Find biotech, clinical research and pharmaceutical jobs from thousands of employers; “Investment in Biopharma is Reaching an Inflection Point,” https://www.biospace.com/article/investment-in-biopharma-is-reaching-an-inflection-point-/]

In particular, America’s east coast hubs excel due to an enviable university system, innovative biotech companies and the presence of large pharma companies like Pfizer, Johnson & Johnson and Merck & Co. Adding to the allure are plentiful enterprise partnerships, a robust entrepreneur ecosystem and a well-functioning incubator system.

New Jersey leads the nation in big names. There are 139 U.S. Food and Drug Administration-registered biopharmaceutical manufacturing facilities in the state, and 25% of all cell and gene therapies are being developed there. Among the largest biopharma companies in the country, 13 are in New Jersey, along with 3,280 life science establishments. More than 50% of all new FDA novel medicines approved in 2019 were from companies with a footprint in New Jersey.

New York, home of Pfizer and Bristol Myers Squibb is ranked second in the nation for bioscience jobs. A $1.8 billion expansion in Tarrytown, NY by Regeneron Pharmaceuticals announced mid-July is set to add 1,000 jobs over the next five years, with the company also adding to its research, preclinical manufacturing and support facilities.

What New Jersey is to big pharma, the same can be said of Massachusetts when it comes to biotech. In 2020, biopharma employment grew by 5.5% to about 85,000 jobs, and the state’s industry raised $5.8 billion in venture capital.

Over the past 15 years, Massachusetts has seen a 92% increase in biopharma employment, Massachusetts Biotechnology Council said in its latest industry snapshot.

MassBio said the record-breaking rates at which Massachusetts-headquartered firms are raising VC funds is leading to “incredible growth in the real estate pipeline to meet the demand of biopharma companies that are choosing to launch and scale across Massachusetts.”

One such company, Nuvalent, launched with $50 million in Series A financing from Deerfield Management to develop innovative small molecule kinase inhibitors for programs in non-small cell lung cancer (NSCLC)

The Boston metropolitan area, and in particular Cambridge, seems to be holding its own as the pre-eminent biotech hub in the world. At the end of August, biotech start-up Laronde raised $440 million in a Series B round. Laronde is creating endless RNA, a novel, engineered form of RNA that is programmable to express therapeutic proteins to the human body.

Biogen and Vertex are the largest biopharma employers in Massachusetts, followed by Moderna.

In addition, seven Korean pharmaceutical and biotech companies have recently moved into the Cambridge Innovation Center to expand their reach into the U.S.

Eager to grab some of the action, Texas is determined to plant its flag as the next US biotech hub. Oncology leads the way here, with over 4,700 drug indication programs under development, equal to 71% of all global pipelines. Emerging biopharmas' pipelines are robust here, ranging from start-up to mature, according to a recent BIO Industry analysis.

Sign in to recut, update, or save this card.